STAAR Surgical Company (STAA) Stock Price & Analysis
STAAR Surgical Company (STAA) closed at USD 24.61 on Wednesday, October 28, 2026, up 1.86% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 24.16; the Oct 28, 2026 session ranged USD 23.94–24.99 on volume of 675,331 shares. Market capitalization is $1.23B, with a 52-week range of USD 15.59–35.87 (NGM). Source: Nexqual, retrieved October 29, 2026 at 06:43 UTC.
Also available as compact Markdown for AI agents: nexqual.com/STAA.md
Key facts (STAA)
- Last four reported quarters (through Jul 3, 2026): revenue $340M, net income $3.8M (1.1% margin), free cash flow -$6.7M (SEC filings).
- Valuation: P/E 321.4x (avg 72.3x at the last 1 fiscal year-ends).
- Analysts: Hold (mean 2.73 on a 1–5 scale) (11 analysts), mean target USD 27.67 (range 19–37).
- Total return with dividends: 1Y -7.5% vs S&P 500 +13.6%; 5Y -79.2% vs S&P 500 +79.8%.
- Next earnings: 2026-11-04, EPS estimate USD 0.17, revenue estimate $78.7M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (STAA)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $230M | $239M | $322M | $314M | $239M | $340M |
| Gross profit | $179M | $223M | $253M | $240M | $182M | — |
| Operating income | $33.3M | $43.8M | $28.1M | -$12.6M | -$91.7M | $13.7M |
| Net income | $27.5M | $39.7M | $21.3M | -$20.2M | -$80.4M | $3.8M |
| EPS (diluted) | $0.56 | $0.80 | $0.43 | -$0.41 | -$1.62 | — |
| Free cash flow | $30.3M | $17.6M | -$3.6M | -$7.7M | -$40.0M | -$6.7M |
| Gross margin | 77.5% | 93.3% | 78.4% | 76.3% | 76.2% | — |
| Operating margin | 14.5% | 18.3% | 8.7% | -4.0% | -38.3% | 4.0% |
| Net margin | 11.9% | 16.6% | 6.6% | -6.4% | -33.6% | 1.1% |
| Revenue growth | +41.0% | +3.9% | +34.7% | -2.6% | -23.7% | — |
| Cash + short-term investments | $200M | $212M | $221M | $230M | $188M | — |
Fiscal years end Jan. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jul 3, 2026) (STAA)
P/E 321.4x · P/S 3.6x · P/B 3.4x · FCF yield -0.55% · Earnings yield 0.31%
P/E at fiscal year-ends: Dec 2023 72.3x.
Analysts (STAA)
Consensus Hold (mean 2.73 on a 1–5 scale), 11 analysts; mean target USD 27.67 (low 19, high 37).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-29 | Stifel | Upgrade | Hold → Buy | $28 → $31 |
| 2026-09-22 | Jefferies | Target lowered | Buy | $28 → $23 |
| 2026-08-17 | Stifel | Target lowered | Hold | $31 → $28 |
| 2026-08-13 | UBS | Target lowered | Sell | $20 → $19 |
| 2026-08-13 | Jefferies | Target lowered | Buy | $29 → $28 |
| 2026-08-13 | Wedbush | Target lowered | Outperform | $40 → $37 |
| 2026-08-04 | Wedbush | Reiterated | Outperform | $40 |
| 2026-07-28 | UBS | Initiated | Sell | $20 |
| 2026-07-22 | Wedbush | Reiterated | Outperform | $40 |
| 2026-07-16 | Wedbush | Reiterated | Outperform | $40 |
Total return (dividends reinvested) (STAA)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -7.5% | -79.2% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | -7.5% | -26.9% |
| Volatility (annualized) | 55.0% | 60.1% |
| Max drawdown | -42.8% (May 2026→Sep 2026) | -87.0% (Oct 2021→Feb 2025) |
STAA earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | $0.25 | $0.23 | Beat +8.7% | — |
| — | Quarter ended Mar 31, 2026 | $0.29 | $0.08 | Beat +262.5% | — |
| — | Quarter ended Dec 31, 2025 | $0.01 | $0.17 | Miss −94.1% | — |
| — | Quarter ended Sep 30, 2025 | $0.47 | $0.28 | Beat +67.9% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
STAA recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 27, 2026 | Schedule 13G/A | BlackRock, Inc.: 9.2% of shares, passive 5%+ holder (amended) |
| Oct 5, 2026 | 8-K/A | Director or executive officer change, or pay arrangement; Regulation FD disclosure “On September 8, 2026, STAAR Surgical Company (the "Company") announced that it appointed David Bailey as Chief Commercial Officer, effective that day Since 2010, Mr. Bailey has been the Founder and President of DB Consulting, a Switzerland-based strategic advisory firm providing advice to private equity firms and multinational companies, including the Company, on strategic planning, operational improvement, overall market expansion, return on investment and product innovation. Prior to DB Consulting, he served as…” |
| Sep 10, 2026 | 8-K | Director or executive officer change, or pay arrangement; Regulation FD disclosure “On September 8, 2026, STAAR Surgical Company (the "Company") announced that it appointed David Bailey as Chief Commercial Officer, effective that day Since 2010, Mr. Bailey has been the Founder and President of DB Consulting, a Switzerland-based strategic advisory firm providing advice to private equity firms and multinational companies, including the Company, on strategic planning, operational improvement, overall market expansion, return on investment and product innovation. Prior to DB Consulting, he served as…” |
| Aug 14, 2026 | Schedule 13G/A | Madison Avenue International LP, Madison Avenue Partners, LP: 8.4% of shares, passive 5%+ holder (amended) |
| Aug 12, 2026 | 10-Q | Quarterly report · period ended Jul 3, 2026 |
| Aug 12, 2026 | 8-K | Quarterly results; Regulation FD disclosure |
| Aug 6, 2026 | 8-K | Director or executive officer change, or pay arrangement; Regulation FD disclosure “On August 4, 2026, STAAR Surgical Company (the "Company" or "STAAR") announced that the Company's Board of Directors (the "Board") appointed Warren Foust as President and Chief Executive Officer ("CEO") and new member of the Board, effective August 4, 2026 (the "Effective Date"). Mr. Foust, age 50, joined STAAR in April 2023 as Chief Operating Officer ("COO") and has served as Interim Co-CEO, President & COO since February 2026, and as President and COO since March 2025. Prior to joining STAAR, Mr. Foust served as…” |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
STAA company outlook (results filed Aug 12, 2026)
- “Even so, excluding the one-time $25.9M order booked in the third quarter of 2025, we still anticipate strong year-over-year growth — evidence that our underlying momentum is durable across the seasonal cycle.”
Quoted word-for-word from the SEC 8-K results press release.
STAA analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.17 | $0.17 | +0.0% | $78.7M | 7 |
| Next quarter (ends Dec 2026) | $0.09 | $0.08 | +20.0% | $68.4M | 7 |
| Current fiscal year (ends Dec 2026) | $0.84 | $0.73 | +15.3% | $334.3M | 7 |
| Next fiscal year (ends Dec 2027) | $1.11 | $0.99 | +12.4% | $360.6M | 7 |
Key Statistics (as of October 29, 2026 at 06:43 UTC)
| Price | USD 24.61 |
|---|---|
| Change | ▲ 1.86% (up) |
| Previous Close | USD 24.16 |
| Open | USD 24.13 |
| Day Range | USD 23.94 – 24.99 |
| 52-Week Range | USD 15.59 – 35.87 |
| Volume | 675,331 shares |
| Market Cap | $1.23B |
| Exchange | NGM |
Technical Analysis (STAA)
Nexqual's technical model rates STAA "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 29, 2026 at 06:43 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 64 (neutral) |
| vs SMA50 | Above (USD 22.38) |
| MACD | 0.36 (positive) |
Analyst Ratings (STAA)
Wall Street analysts rate STAA "Hold" based on 11 analysts, with a mean price target of USD 27.67 (range USD 19–37), per Nexqual as of October 29, 2026 at 06:43 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 27.67 |
| High Target | USD 37 |
| Low Target | USD 19 |
| Buy / Hold / Sell | 4 / 6 / 1 |
Earnings (STAA)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD 0.17 |
| Revenue Estimate | $78.73M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.25 vs est 0.23 ▲ beat |
| 2026-03-31 | USD 0.29 vs est 0.08 ▲ beat |
| 2025-12-31 | USD 0.01 vs est 0.17 ▼ miss |
| 2025-09-30 | USD 0.47 vs est 0.28 ▲ beat |
Source: Nexqual, October 29, 2026 at 06:43 UTC.
Financials & Fundamentals (STAA)
| Total Revenue | $339.59M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +111.00% |
| Gross Margin | +76.62% |
| Operating Margin | +10.89% |
| Profit Margin | +1.13% |
| ROE | +1.09% |
| Debt / Equity | 0.1 |
| Current Ratio | 4.67 |
| Total Cash | $181.49M |
| Total Debt | $35.94M |
| Free Cash Flow (last four quarters to Jul 2026, SEC 10-Q / 10-K) | -$6.75M (-2.0% of revenue) |
Source: Nexqual, October 29, 2026 at 06:43 UTC.
Financial Health Score (STAA)
Nexqual rates STAAR Surgical Company's overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 06:43 UTC.
| Growth | Critical — Revenue -24% YoY (annual), sharp decline |
|---|---|
| Profitability | Strong — Gross margin 77%, operating 4% (last 4 quarters to Jul 2026, SEC; the Sep 2025 quarter alone accounts for 135% of operating income) |
| Balance Sheet | Strong — $181M cash vs $36M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$7M (last 4 quarters to Jul 2026, SEC), burning cash |
| Efficiency | Weak — ROE 1%, ROA 0.8% (last 4 quarters, SEC) |
Ownership (STAA)
| Insider Ownership | +0.85% |
|---|---|
| Institutional Ownership | +111.58% |
| Shares Outstanding | 50.14M |
| Float | 26.13M |
| Short % of Float | +15.37% |
Source: Nexqual, October 29, 2026 at 06:43 UTC.
Leadership (STAA)
STAAR Surgical Company is led by Warren Foust, CEO, President & Director, per Nexqual as of October 29, 2026 at 06:43 UTC.
| CEO, President & Director | Warren Foust |
|---|---|
| Executive VP & CFO | Deborah J. Andrews |
| Chief Technology Officer | Ben Park |
| Director of Investor Relations | Connie Johnson |
| Vice President of Global Human Resources | William W. Goodmen |
Major Backers & Investors (STAA)
Notable institutional backers of STAAR Surgical Company include Broadwood Capital, Inc., Madison Avenue Partners, LP, Yunqi Capital Ltd, according to Nexqual as of October 29, 2026 at 06:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Broadwood Capital, Inc. | 32.16% |
| Madison Avenue Partners, LP | 8.33% |
| Yunqi Capital Ltd | 6.5% |
| Point72 Asset Management, L.P. | 4.86% |
| Goldman Sachs | 4.29% |
| Anatole Investment Management Ltd | 3.29% |
| Fidelity | 0.74% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 13.42% |
| Vanguard Group | 7.05% |
| State Street | 3.53% |
Source: Nexqual, October 29, 2026 at 06:43 UTC.
From STAAR Surgical Company's Latest SEC 10-K Filing (filed 2026-03-03)
Key Strengths & Strategy (as disclosed to the SEC)
- We protect our proprietary technology, in part, through confidentiality and nondisclosure agreements with employees, consultants, and other parties.
- The FDA has issued a final rule to implement the Quality Management System Regulation (QMSR), which is intended to harmonize U.S. quality system requirements more closely with ISO 13485, and the transition to QMSR could require updates to our quality system documentation and processes.
- We are the leading manufacturer of phakic implantable lenses used worldwide in corrective or "refractive" surgery.
Legal & Regulatory Risks (Item 1A, quoted)
- We are subject to extensive government regulation worldwide, which increases our costs and could prevent us from selling our products.
- Regulatory issues may adversely impact our operations.
- Laws pertaining to healthcare fraud and abuse could materially adversely affect our business, financial condition, and results of operations.
- We have voluntarily recalled our products in the past and recalls could take place again.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AZTA | Azenta, Inc. | USD 40.63 | ▲ 3.97% |
| XRAY | DENTSPLY SIRONA Inc. | USD 9.44 | ▲ 0.96% |
| LMAT | LeMaitre Vascular, Inc. | USD 82.87 | ▼ 1.1% |
| WRBY | Warby Parker Inc. | USD 24.43 | ▼ 2.55% |
| ATRC | AtriCure, Inc. | USD 61.42 | ▼ 0.15% |
| PLSE | Pulse Biosciences, Inc | USD 53.67 | ▲ 0.88% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 06:43 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt